|Systematic (IUPAC) name|
|Molecular mass||339.452 g/mol|
|(what is this?)|
UK-414,495 is a drug developed by Pfizer for the treatment of female sexual arousal disorder. UK-414,495 acts as a potent, selective inhibitor of the enzyme neutral endopeptidase, which normally serves to break down the neuropeptide VIP. The consequent increase in VIP activity alters blood flow to the genital region leading to increased lubrication and muscle relaxation.
- Melanotan II
- 'Female Viagra' will help women increase their sexual arousal. Daily Mail Online 14 April 2010
- Armer R, Warne P, Witherington J (2006). "Recent disclosures of clinical drug candidates". Drug News & Perspectives 19 (1): 65–72. PMID 16550257. ISSN 0214-0934
- Angulo, J. (2010). "Neutral endopeptidase inhibition: could it have a role in the treatment of female sexual arousal disorder?". British Journal of Pharmacology 160: 48. doi:10.1111/j.1476-5381.2010.00693.x.
- Wayman, C.; Baxter, D.; Turner, L.; Van Der Graaf, P.; Naylor, A. (2010). "UK-414,495, a selective inhibitor of neutral endopeptidase, potentiates pelvic nerve-stimulated increases in female genital blood flow in the anaesthetized rabbit". British Journal of Pharmacology 160 (1): 51–59. doi:10.1111/j.1476-5381.2010.00691.x. PMC 2860206. PMID 20412068.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|